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A systematic review of the role of penile rehabilitation in prostate cancer patients receiving 
radiotherapy and androgen deprivation therapy 
 
 
Introduction 
Prostate cancer is the second most common cancer in the UK and the most common cancer in men, 
accounting for approximately 46,700 new cases in 2014 and 13% of all new cancer cases in the UK (1). 
With greater than 8 in 10 men diagnosed with prostate cancer surviving their disease for ten years or 
more in England and Wales, the side effects of prostate cancer treatment can have profound effects 
on patient’s quality of life for extended periods of time into survivorship (1).  
 
Treatment induced erectile dysfunction (ED) is an inability to gain and maintain an erection sufficient 
for sexual activity. It is linked with changes to penile blood flow, androgen deprivation therapy (ADT) 
mediated loss of libido, nerve damage, psychological changes including depression, anxiety, 
relationship difficulties, and treatment induced tiredness. Erectile function is a significant marker for 
quality of life (QoL) (2). With the combined approach of radiotherapy and ADT, the psychological 
impact of ED can be devastating for patients (3, 4). Erectile function that has been lost cannot easily 
be regained, highlighting the importance of timely intervention (5). 
 
Penile rehabilitation is defined as “the use of any device, pharmacologic agent, or intervention to 
promote male erectile function (including girth, length, curvature and quality and longevity of 
tumescence) as a primer before and after any insult to the penile erectile physiologic axis” (5). The 
concept of penile rehabilitation came to prominence following the release of sildenafil in 1998 (6). 
Since then there has been much debate on the potential benefit of penile rehabilitation (5), but little 
in the way of convincing supporting evidence. Current options for treatment of ED in prostate 
radiotherapy patients are summarised in Table 1. 
 
No gold standard guidelines exist for the management of ED in patients following radiotherapy and 
ADT (7-9). Current management for prostate cancer induced ED is consultant dependant and 
unsupported by high quality data (10-12). NICE guidelines advise that men have early and continuing 
access to specialist erectile dysfunction services with phosphodiesterase type 5 (PDE5) inhibitors as 
first-line therapy (13). 
 
Despite these recommendations, penile rehabilitation is not widely discussed by health care 
professionals. ED is much less likely to be broached with patients than other side effects (14). Reasons 
for this include inadequate knowledge, a fear of invading patient privacy and embarrassment (14, 15). 
Thus, men are rarely asked to discuss psychosexual side effects during treatment (16) making it 
difficult to assess the extent of the problem and address it (17-20). 
 
The significant physical side effects of prostate cancer treatment have a negative impact on 
psychological wellbeing with psychosexual problems growing in importance over time (16, 21). 
Prompt identification coupled with advice and treatment can minimise their impact and consequently 
improve psychological wellbeing and quality of life. This effect continues into survivorship, 
strengthening the case for tackling the effects of ED in a more methodological and structured way 
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(21). This systematic review, therefore, aimed to appraise the evidence base for penile rehabilitation 
management and identify evidence-based recommendations for practice.  
 
Table 1. Erectile dysfunction interventions commonly used by prostate radiotherapy patients 
 
Intervention Mechanism Benefits Barriers to Use 
PDE5 
Inhibitors 
 
Oral pharmaceutical 
preventing breakdown of 
nitric oxide (NO). NO is 
produced during erection 
and PDE5 inhibitors prevent 
NO breakdown leading to an 
increase in blood flow and 
penile tumescence and 
passive occlusion of efferent 
blood flow leading to 
erection. 
Convenience of use Require sexual stimulation to 
function. Reduces spontaneity of 
sexual activity. Contraindicated 
with certain common 
medications including nitrates for 
angina 
Alprostadil IV Intravenous pharmaceutical 
that induces penile vascular 
smooth muscle relaxation, 
increases blood flow and 
generates erection without 
reliance on NO production or 
an intact nervous pathway. 
Faster acting than 
PDE5 inhibitors 
Require manual dexterity to use. 
Interfere with spontaneity of 
sexual activity. Injection into 
penis can be a psychological 
barrier. Can cause pain, bruising, 
bleeding, scars, bending of the 
penis or priapism 
Intraurethral 
alprostadil 
Urethral pessary with same 
mechanism as above. 
Faster acting than 
PDE5 inhibitors 
As above. Insertion into penile 
meatus can be psychological 
barrier for some patients to use. 
Can cause local irritation to 
urethra  
Vacuum 
Erection 
Devices 
(VEDs) 
Vacuum device placed over 
penis to cause negative 
pressure and draw blood into 
the penis 
Can work where 
pharmacological 
interventions fail 
Require physical dexterity to 
operate. Interfere with 
spontaneity of sexual activity. 
Can be uncomfortable to use. 
Causes unnatural appearance of 
erection 
Penile 
prosthesis 
Inflatable or rigid implant 
placed into corpora. 
Bypasses the physiological 
requirements for erection 
Works if previous 
interventions failed 
On-demand erections 
possible and 
sufficiently rigid for 
anal intercourse 
Irreversible, invasive and 
expensive surgical procedure 
 
Psychosexual 
counselling 
Psychological interventions 
to tackle emotional and 
psychological barriers to 
erection 
Tackles root 
psychological causes 
Realigns current 
function with desired 
function. 
Patient reluctance to engage with 
difficult or upsetting topics. 
Patients can be in denial or 
believing the problem to be 
physiological in nature 
 
 
Method 
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A systematic review of the evidence base was undertaken using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (22). The SCOPUS and Medline (EBSCO) 
databases were searched using boolean combinations of the key words shown in Table 2.  
 
Additional papers were located from reference lists of returned papers and retrieved . Articles dating 
from 1998 were included since this corresponds with the advent of sildenafil and the first common 
usage of the term penile rehabilitation. Articles were included if they related to patients with ED 
receiving prostate radiotherapy with or without ADT.  Articles were excluded if they were not written 
in English, or if their focus was patients who had undergone prostatectomy or other pelvic surgery 
likely to cause ED as well as patients with known pre-existing ED. The PRISMA diagram in Figure 1 
shows the numbers of papers rejected at each stage of the selection process. For the remaining 
papers, study quality was graded using Oxford Centre for Evidence-based Medicine – Levels of 
Evidence and the Scottish Intercollegiate Guidelines Network  (23, 24).  
 
 
 
Table 2. Search terms  
 
Theme Keyword 
Intervention Penile rehabilitation; PDE5 inhibitors; Sildenafil; Vardenafil; Tadalafil; 
Prostaglandin e1; Alprostadil; MUSE; Vacuum erection device; Vacuum 
constriction device; psych*; counsel* 
Erectile dysfunction Erectile dysfunction; Impoten*; Sexual w/2 dysfunction 
ADT Androgen deprivation therapy; Hormon*; Chemical castration 
Radiotherapy Radiotherap*; Radiation therap* 
Prostate cancer Prostate cancer; Neoplas* w/2 prostate 
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Figure 1. PRISMA Diagram demonstrating selection of final articles from database searches 
 
 
 
Results 
This study identified nineteen papers on penile rehabilitation in prostate radiotherapy patients, 
consisting of eight randomised controlled trials (RCTs), three systematic reviews and eight case 
studies. Table 3 summarises the key findings from these studies along with appraisal of their methods. 
Studies in this area are generally deemed of low quality due to use of small recruitment convenience 
samples that are not sufficiently robust to generate evidence-based findings (25). Four of the eight 
trials were by the same author (25-28) 
 
Table 3: Summary of Evidence 
 
Study Design Participants Findings SIGN 24 
Rating 
Conflicts of 
Interest 
Ohebshalom 
et al. 2005 
 
Case series 110 More effective in patients post 
brachytherapy (BT) than external 
beam radiotherapy. Sildenafil appears 
to be useful in this group, participants 
on ADT excluded 
Level 4 
(HIGH) 
None listed 
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Weber et al. 
1999 
Case series 100 Sildenafil appears to be useful in this 
group. Less useful in ADT patients. 
Level 4 
(HIGH) 
None 
declared 
Schover et 
al. 2002 
 
Case series 1236 Men prefer non-invasive treatments. 
Benefits of incorporating sexual 
counselling in to treatment. Sildenafil 
works to varying degrees from 
different studies. 
Level 4 
(HIGH) 
None 
Teloken et 
al. 2007 
Case series 152 ADT compounded the effects of ED Level 4 
(HIGH) 
None  
Valicenti et 
al. 2001 
Case series 24 Sildenafil citrate is effective for 
restoring erectile function and 
associated satisfaction back to 
baseline before treatment. 
 
Level 4 
(HIGH) 
None  
Pahlajani et 
al. 2010 
 
Case series 69 There was a 50% decline in erectile 
function at 6 and 12 months post BT 
treatment. Sildenafil did appear useful 
 
Level 4 
(HIGH) 
None  
Schiff et al. 
2006 
 
Case series 210 The early use of PDE5 inhibitors after 
BT is associated with a significant 
improvement in and maintenance of 
erectile function compared with late 
use 
 
Level 4 
(HIGH) 
None  
Teloken et 
al. 2009 
 
Case series 152 Older age, higher radiation dose, 
increased time since radiation, and 
longer time of ADT are independent 
predictors of decreased sildenafil 
response after RT for prostate cancer 
Level 4 
(HIGH) 
None  
Watkins et 
al. 2011 
RCT 61 Only about one in four patients 
respond better to sildenafil than to 
placebo; more study needed. 
 
 
Level 1 
(HIGH) 
None  
Zelefsky et 
al.  2014  
RCT 279 Patients reported significantly 
improved erectile function for 
sildenafil compared to placebo. 
Radiotherapy induced trauma to the 
cavernous tissue vascular supply may 
undergo rehabilitation and repair 
during sildenafil administration. 
Sildenafil not as useful in patients on 
ADT. 
Level 1 
(HIGH) 
Drugs 
supplied by 
pharma 
company 
Ilic et al. 
2013 
 
RCT 27 There was no evidence that sildenafil 
provides long-term erectile function 
for patients 
Level 1 
(HIGH) 
None  
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Regular use of sildenafil may improve 
short-term erectile function 
Ricardi et al.  
2010  
Randomised, 
not blinded, 
no control 
52 Both tadalafil formulations generated 
significantly higher response rates 
compared with baseline. Once-a-day 
5-mg dosing showed higher 
compliance and marginally better 
toxicity profile 
Daily dosing allowed for more 
spontaneity and less need for 
planning sexual activity. 
 
Level 1 
(HIGH) 
None  
Incrocci et 
al. 2001 
 
RCT, double 
blind, 
placebo 
controlled 
crossover 
60 Sildenafil was shown to be effective. 
Higher dose of 100mg vs 50mg 
needed post radiotherapy 
Level 1 
(HIGH) 
Supported 
by pharma 
company 
grant 
Incrocci et 
al. 2003 
 
RCT, double 
blind, 
placebo 
controlled 
crossover 
46 Sildenafil was shown to be effective. 
Higher dose of 100mg vs 50mg 
needed post radiotherapy 
Level 1 
(LOW) 
Supported 
by pharma 
company 
grant 
Incrocci et 
al. 2006 
RCT, double 
blind, 
placebo 
controlled 
crossover 
60 Tadalafil is a good treatment option 
for patients with ED after 
radiotherapy. Potential advantage of 
tadalafil is its efficacy up to 36 h after 
dosing, allowing patients less need to 
plan sexual activity in advance. 
 
Level 1 
(HIGH) 
Drugs and 
grant 
support 
supplied by 
pharma 
company 
Incrocci et 
al. 2007 
RCT, double 
blind, 
placebo 
controlled 
crossover 
51 Tadalafil is a good treatment option 
for patients with ED after 
radiotherapy. Potential advantage of 
tadalafil is its efficacy up to 36 h after 
dosing, allowing patients less need to 
plan sexual activity in advance. 
Level 1 
(LOW) 
Supported 
by pharma 
company 
grant 
Yang et al. 
2013 
Systematic 
Review 
 
PDE5 inhibitors were safe and 
efficacious in the treatment of ED 
after radiotherapy for prostate cancer  
Level 2 
(HIGH) 
None  
Candy et al. 
2008 
Systematic 
Review 
 
The positive effects on erectile 
function do not necessarily confer 
benefits for the patient or their 
partner. 
 
Level 2 
(HIGH) 
None  
White et al. 
2015 
Systematic 
Review 
 
Chosen experts show limited 
treatment levels for patients. 
Level 2 
(HIGH) 
None listed 
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Sildenafil was shown to be effective in improving erectile function in three RCTs (25, 26, 29). One study 
found sildenafil to be effective only in the short term, with little benefit seen at two-year follow-up. 
Another showed poor outcomes with only one in four patients experiencing a better response to 
sildenafil than placebo (2, 30). Tadalafil was found to be effective in all three of the RCTs in which it 
was used (27, 28, 31).  
 
Comparison between studies was performed where uniform scales such as the International Index of 
Erectile Function (IIEF) (32, 33) were used. For other studies, direct comparison between studies 
proved difficult, however, as despite the common usage of IIEF, different metrics were reported. No 
studies were found that assessed the effectiveness of vacuum erection devices (VEDs), intraurethral 
alprostadil, intercavernosal injection or penile prosthesis for managing erectile dysfunction induced 
by radiotherapy. No studies were found relating to issues beyond erectile function such as 
psychosexual counselling, impacts on relationships, QoL or associated patient reported issues 
including decreased penile length and testicular shrinkage. 
 
 
Discussion 
Despite the range of physical and pharmaceutical interventions, relevant research focussed solely on 
the use of PDE5 inhibitors (5) and confirmed therapeutic value for sildenafil and tadalafil. Themes 
from the reviewed papers related to choice of PDE5 inhibitors, timing of intervention and the impact 
of ADT. The following discussion addresses these themes. 
 
Choice of PDE5 inhibitor 
Studies on tadalafil, a more recent PDE5 inhibitor, are reported as showing promise in penile 
rehabilitation. Tadalafil remains active in the system for 36 hours, allowing for more spontaneous 
sexual intercourse without the need for on-demand dosing. Pisansky et al. conducted a large RCT using 
5mg daily dose tadalafil for men undergoing single modality radiotherapy for prostate cancer (34). 
This failed to demonstrate improvements in overall erectile function and satisfaction for patients and 
partners compared to placebo (34). 
 
Incrocci et al. conducted a total of four RCTs into sildenafil and tadalafil between 2001 and 2007 and 
showed a statistically significant improvement in both studies for around 50% of men receiving the 
drugs (25, 27). A subsequent open-label extension to both trials, involved 51 participants using 
sildenafil and 46 progressing on tadalafil (26, 28). Both groups were shown to have a good response 
in the open label phase, higher than or equal to that in the respective initial phases. 
 
 
Timing of intervention 
Encouraging results (35) indicated that radiotherapy induced trauma to the erectile vascular supply 
may undergo rehabilitation and repair with early administration of sildenafil. Similar research in 
patients with erectile dysfunction not associated with prostate cancer treatment supports these 
findings (36). This provides hope that patients can regain lost function rather than endure palliation 
of symptoms.  
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A range of evidence (6, 35, 37, 38) indicates the benefits of early intervention for reducing long-term 
loss of function. Despite this, sildenafil exhibits a significant drop in efficacy two years post 
radiotherapy (30, 39), possibly due to delayed side-effects. The early use of PDE5 inhibitors after 
brachytherapy (BT) is associated with a significant 50% observed decline in erectile function compared 
with late use (35, 38).  
 
Zelefsky et al. approached penile rehabilitation from an alternate perspective with prophylactic, 
rather than reactionary, use of sildenafil (29). Sildenafil was commenced three days prior to 
radiotherapy and continued daily for six months, demonstrating significantly improved erectile 
function with 78% of patients on sildenafil reporting functional erection versus 48% on placebo (29). 
While an overall improvement in scores was seen in both arms at 24-month follow-up, the overall 
benefit in the sildenafil arm over placebo diminished. These results suggest that sildenafil is effective 
when taken continuously but also that it does not reverse the physiological changes to the erectile 
mechanism, over a 6-month period. With psychological factors playing a major contributing role to ED 
it is also possible that there is a considerable placebo effect of taking the drug. 
 
Evidence suggests improved compliance for daily dosing over on-demand when taken alongside other 
long-term medication as part of an already established routine (41). The sustained blood level of the 
drug permits spontaneous activity without the need to plan sexual activity in advance (40). Distancing 
the strict timing schedule of prescribed medication from sexual intercourse can promote the feeling 
of independent erectile function without the intrusiveness of the intervention drawing focus to the 
problem (41). Men show a preference for non-invasive treatments, despite invasive treatments being 
more effective (42). This would appear to be true not only from a physically invasive perspective, but 
also in an emotionally invasive way as evidenced by improved compliance on daily dose tadalafil 
versus on-demand (31). 
 
ADT patients 
For ADT patients a low or absent libido, coupled with castrate levels of testosterone, will diminish, or 
completely preclude, sexual activity, rendering the use of on-demand dosing less effective (43). Daily 
dosing of PDE5 inhibitors can, however, assist with preservation of nocturnal erections which can 
maintain oxygenation and nutrition of the corpus callosum and protect erectile function during the 6 
to 24 month ADT regime (44). With the greatest physiological changes in erectile function occurring 
within this time frame, it is important that these patients undergo intervention despite the ADT-
mediated lack of sexual desire (41). This can prevent ED upon completion of ADT and consequent 
return of libido. Study outcomes vary considerably amongst patients on ADT, making 
recommendations for this group problematic.  There have been mixed findings of sildenafil usage in 
this group (45) although a 2013 paper concluded that PDE5 inhibitors were safe and efficacious (46).  
Low libido and motivation may limit recruitment into these trials compared to post radical 
prostatectomy studies (47). The studies for this group all conclude that this group experienced a 
significant deleterious effect on erectile function which highlights the importance of early intervention 
(40, 48, 49).  
 
Alternative approaches 
There is a general theme of ease of use of oral PDE5 inhibitors that make them a convenient choice 
for patients and practitioners alike (9, 25-28, 31). It is important not to rely solely on PDE5 inhibitors 
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as men that try a greater number of treatments for ED were more likely to find one that works and 
more likely to continue using treatments for ED that produced greater improvements in erectile 
function. While this may seem intuitively logical, it highlights the need to be persistent in the approach 
to managing erectile dysfunction in this patient group and touches on the need for combining 
treatment types to achieve maximum results (42). No studies were identified that evaluated 
alternatives to PDE5 inhibitors such as alprostadil, VEDs, psychosexual counselling or any other 
intervention for penile rehabilitation.  
 
Psychosexual issues play an important role for these patients (31, 42, 48) and can influence motivation 
for seeking assistance with erectile function during radiotherapy (4, 50, 51). Early acknowledgement, 
counselling and management of these side effects can markedly improve patients QoL (13, 38). While 
numerous studies for these interventions already exist outside of the area of radiotherapy and ADT 
(52, 53), further study is needed to determine if any of the learning can be transferred to this patient 
group. 
 
While the evidence has shown that PDE5 inhibitors can address the issue of physical erectile 
dysfunction, it is clear that they do not address any psychological issues or aid in preservation of penile 
length and girth. VEDs have been shown to be useful in this respect for patients post radical 
prostatectomy suggesting a benefit of combining treatment types, however no studies exist for 
patients treated with radiotherapy and ADT (5). Further research into a multi-modality approach is 
urgently required. 
 
Limitations of the evidence base 
The four Incrocci trials account for half of the eight RCTs available for this patient group (25-28). When 
taken as four individual studies this can artificially skew findings towards that of one author. Out of 
eight papers based on case studies returned in this literature search, two are by the same author (40, 
49) and appear to involve the same cohort. Using the same convenience sample cohort for two 
separate studies can disproportionately represent this small group in the published data (54). 
 
Comparison of findings is limited by inconsistencies in the way data was collected between studies 
with limited use of baseline measures, low sample sizes and an absence of knowledge of existing co-
morbidities reducing validity (2, 25-28, 30, 39, 40, 48, 49, 55). Recruitment and compliance issues 
associated with this group are a further confounding issue with a recent study closing early due to 
slow recruitment with only 35% of the planned participants (2). In addition to low sample sizes, 
participation bias must be considered for these studies with increased motivation of participants 
skewing results in comparison to the general population. 
 
The literature all utilises a quantitative reductionist approach, using the IIEF to categorise the degree 
of erectile dysfunction at various stages (33). This distils complex issues into a convenient grading 
which can overly simplify the issues being investigated and not take the wealth of qualitative data that 
was used to create it into account (56). Consideration of erectile dysfunction in the reviewed evidence 
failed to include all activities, such as masturbation or oral sex, that do not require the same level of 
rigidity as penetrative vaginal sex and may constitute acceptable erectile function for some patients. 
The current evidence base also failed to account for the needs of men who practice anal sex and the 
requirement for greater penile rigidity to do so. In treating patients, it is more important to assess end 
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goals and determine satisfaction with sex life on a relative scale than to universally grade erectile 
function on an absolute scale. 
 
 
Conclusion 
This review has demonstrated that the evidence base relating to penile rehabilitation consists of a 
number of quantitative studies focussed on PDE5 inhibitors only. The current quantitative approach 
has so far failed to deliver robust data on the role of penile rehabilitation in this patient group and 
repeated quantitative RCTs investigating PDE5 inhibitors are unlikely to yield new information. The 
data has confirmed the effectiveness of PDE5 inhibitors for ED with timing of intervention being of 
paramount importance for preservation of erectile function. Additional research into the wider range 
of penile rehabilitation interventions is urgently required to ensure patients have access to those 
therapies that are most appropriate for them.  
 
The reductionist approach provided by quantitative studies fails to represent the narrative behind the 
results and the variation in human experience that is so essential for this patient group. Complex, 
individual, emotional experiences such as those associated with ED are not readily described in 
numerical terms. Reported outcomes based on subjective, and potentially unknown factors, may 
account for the significant variations in findings between studies. A paradigm shift towards qualitative 
research in the field of penile rehabilitation for prostate cancer patients treated with radiotherapy 
and ADT may be of value in future studies. 
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